{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Guillen N"],"funding":["Fundació Docència i Recerca Mútua de Terrassa","Instituto de Salud Carlos III","NIA NIH HHS","Diputació de Lleida","Foundation for the National Institutes of Health","Fundación BBVA","Departament de Salut, Generalitat de Catalunya","Universitat de Barcelona","Fundació la Marató de TV3","Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas"],"pagination":["257-266"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11799063"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["275(1)"],"pubmed_abstract":["Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta<sub>1-42</sub> (Aβ<sub>1-42</sub>, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal ( +) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and am"],"journal":["European archives of psychiatry and clinical neuroscience"],"pubmed_title":["Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study."],"pmcid":["PMC11799063"],"funding_grant_id":["SLT006/17/125","PERIS SLT002/16/408","Program 1","PI19/00449","AGAUR","PERIS 2019 SLT008/18/00050","20141210","RF1 AG061566","PI20/01473","SLT006/17/119","PI14/01126","2022","INT19/00016","PIRS2021","Alzheimer Disease","FI20/00076","PI17/01019","PI17/01896","PERIS 2016-2020 SLT008/18/00061","20142610","AC19/00103","R21AG056974","PI18/00435","R01AG061566","1R01AG056850-01A1"],"pubmed_authors":["Alvarez I","Lourdes Ispierto M","Alcolea D","Llado A","Carnes-Vendrell A","Vilas D","Culell N","Guillen N","Puig-Pijoan A","Balasa M","Fortea J","Pinol-Ripoll G","Contador J","Fernandez-Lebrero A","Buongiorno M","Lleo A","Sanchez-Valle R"],"additional_accession":[]},"is_claimable":false,"name":"Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.","description":"Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta<sub>1-42</sub> (Aβ<sub>1-42</sub>, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal ( +) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and am","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-22T12:38:08.899Z","creation":"2025-04-06T00:20:36.724Z"},"accession":"S-EPMC11799063","cross_references":{"pubmed":["37898567"],"doi":["10.1007/s00406-023-01701-y"]}}